{
    "clinical_study": {
        "@rank": "139604", 
        "acronym": "TREAT", 
        "arm_group": [
            {
                "arm_group_label": "Imm 124-E 2400 mg/day", 
                "arm_group_type": "Experimental", 
                "description": "Imm-124-E (2400 mg/day) will be provided in two divided doses daily in the form of chewable caplets.  Subjects will get 2 active drug caplets and 2 placebo with each dosing for a total of 8 caplets daily"
            }, 
            {
                "arm_group_label": "Imm 124-E 4800 mg/day", 
                "arm_group_type": "Experimental", 
                "description": "Imm-124-E (4800 mg/day) will be provided in two divided doses daily in the form of 600 mg chewable caplets.  The total number of caplets daily will be 8."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will receive 4 placebo caplets in the morning and 4 in the evening for a total of 8 caplets daily"
            }
        ], 
        "brief_summary": {
            "textblock": "Hypothesis: Oral administration of hyperimmune bovine colostrum enriched with anti-LPS\n      antibodies will reduce endotoxemia, and improve pathophysiological and clinical parameters\n      related to severe alcoholic hepatitis (SAH).\n\n      Aim: To perform a phase 2a \"proof of concept\" placebo-controlled, dose-ranging study of Imm\n      124-E (hyperimmune bovine colostrum enriched with IgG anti-LPS) in subjects with severe AH\n      on steroids."
        }, 
        "brief_title": "Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis, Alcoholic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Alcoholic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects with severe alcoholic hepatitis (20<= MELD <=28) about to receive prednisolone (40\n      mg/day x 28 days) will be randomized 1:1:1 to additionally receive either one of two doses\n      of Imm 124-E (2400 mg/day or 4800 mg/day) orally or placebo for the same duration.  Standard\n      of care nutrition support and alcohol cessation recommendations will be provided to all\n      subjects.  Alcohol withdrawal will be managed per standard of care.  Subjects who meet Lille\n      criteria for failure of treatment on day 7 or side effects requiring discontinuation of\n      steroids will be removed from the study.  The primary endpoint is a decrease in plasma\n      endotoxin levels.\n\n      The secondary endpoints will include:\n\n        1. Mechanistic endpoints:  TNF-\u03b1, immune-inflammatory markers, microbiome-metagenome\n\n        2. Efficacy-related: number of subjects meeting Lille failure criteria at day 7 ,\n           mortality (at 30 days, 90 days, and 180 days), time to drop in conjugated bilirubin by\n           50%, bile acids, liver function tests, change in MELD, and sequential organ failure\n\n        3. Safety related: tolerability, adverse events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Alcoholic hepatitis\n\n          -  Men and women age 21 and above\n\n          -  MELD >= 20 but <=28\n\n          -  Actively consuming alcohol within 6 weeks of entry into the study\n\n          -  Voluntary informed consent\n\n        Exclusion Criteria:\n\n          -  Failure to obtain informed consent\n\n          -  Subjects who are known to be HIV positive\n\n          -  Active infection or sepsis (pneumonia by X-ray, positive blood or urine culture) or\n             multi-organ failure\n\n          -  Other or concomitant liver disease present: viral hepatitis, autoimmune liver\n             disease, metabolic liver disease, vascular liver disease\n\n          -  Cow milk allergy or severe lactose intolerance\n\n          -  Active GI bleeding\n\n          -  Untreated spontaneous bacterial peritonitis based on >250 polymorphonuclear cells or\n             positive culture\n\n          -  Acute kidney injury at time of randomization with Creatinine > 1.5 md/dL\n\n          -  Evidence of acute pancreatitis (by imaging and lipase) or biliary obstruction\n             (dilated bile ducts)\n\n          -  Subjects who are pregnant or lactating\n\n          -  Significant systemic or major illness, that, in the opinion of the Investigator would\n             preclude the patient from participating in and completing the study\n\n          -  Patients requiring the use of vasopressors or inotropic support in 12 hours prior to\n             randomization\n\n          -  Treatment for alcoholic hepatitis within 1 month of study entry with corticosteroids\n             use>1 week immediately prior to the time of entry into the study.\n\n          -  Any patient who has received any investigational drug or device within 30 days of\n             dosing or who is scheduled to receive another investigational drug or device in the\n             course of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01968382", 
            "org_study_id": "IMM 124-E", 
            "secondary_id": "U01AA021891"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Imm 124-E 2400 mg/day", 
                    "Imm 124-E 4800 mg/day"
                ], 
                "description": "Hyper-immune bovine colostrum enriched with anti-LPS antibodies and which has been designated by Immuron as  IMM-124E.", 
                "intervention_name": "IMM 124-E (Hyperimmune Bovine Colostrum)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "subjects will get a total of 8 caplets (4 in the morning and 4 in the afternoon) daily", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "IMM 124-E", 
            "Bovine Colostrum", 
            "Alcoholic", 
            "Hepatitis", 
            "LPS", 
            "Hyper-immune"
        ], 
        "lastchanged_date": "October 18, 2013", 
        "location": [
            {
                "contact": {
                    "email": "anmhowel@iu.edu", 
                    "last_name": "Angela Howell, RN", 
                    "phone": "317-278-9296"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University"
                }, 
                "investigator": {
                    "last_name": "Naga Chalasani, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "gnagey.sara@mayo.edu", 
                    "last_name": "Sara Gnagey, RN, BSN", 
                    "phone": "507-284-2698"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Vijay Shah, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "casargea@vcu.edu", 
                    "last_name": "Carol C Sargeant, RN", 
                    "phone": "804-828-9557"
                }, 
                "contact_backup": {
                    "email": "ldwhite@vcu.edu", 
                    "last_name": "Larry D White, CCRC", 
                    "phone": "804-628-4880"
                }, 
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23298"
                    }, 
                    "name": "Virginia Commonwealth University"
                }, 
                "investigator": [
                    {
                        "last_name": "Arun J Sanyal, MBBS MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Puneet Puri, MBBS MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter Randomized, Double-Blind, Placebo-controlled, Dosing, Safety and Efficacy Study of IMM 124-E (Hyperimmune Bovine Colostrum) for Patients With Severe Alcoholic Hepatitis", 
        "overall_contact": {
            "email": "casargea@vcu.edu", 
            "last_name": "Carol C Sargeant, RN", 
            "phone": "804-828-9557"
        }, 
        "overall_contact_backup": {
            "email": "ldwhite@vcu.edu", 
            "last_name": "Larry D White, CCRC", 
            "phone": "804-628-4880"
        }, 
        "overall_official": {
            "affiliation": "Virginia Commonwealth University", 
            "last_name": "Arun J Sanyal, MBBS MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Means for continuous variables at end of study will be analyzed adjusting for baseline values using ANCOVA.   We expect to show a greater decrease in mean circulating endotoxin levels in those receiving Steroids+ Imm 124-E compared to steroids + placebo.", 
            "measure": "Greater decrease in mean circulating endotoxin levels in those receiving Steroids+ Imm 124-E compared to steroids + placebo", 
            "safety_issue": "No", 
            "time_frame": "7 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968382"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Changes in microbiome composition of stool across study arms at day 28", 
                "measure": "Microbiome-metagenomic-immunologic data", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "description": "# of subjects who meet Lille criteria at day 7\nmortality at days 30, 90 and 180\nchange in MELD scores from baseline to day 7, 30, 90\nSequential organ failure assessment score at day 7, 30\nchanges in serum bile acids from baseline to day 7, 30 and 90\ntime to drop in bilirubin by 50%", 
                "measure": "Efficacy related outcomes", 
                "safety_issue": "No", 
                "time_frame": "180 days"
            }, 
            {
                "description": "Incidence and severity of gastrointestinal events, including nausea, vomiting, and diarrhea\nProportion of subjects who develop renal failure, encephalopathy or pulmonary compromise\nFrequency of sepsis\nFrequency of other adverse events", 
                "measure": "Safety Related endpoints", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Changes in microbial metabolome in blood across study arms at day 28", 
                "measure": "Microbiome-metagenomic-immunologic data", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Changes in cytokine profile across study arms at day 28", 
                "measure": "Microbiome-metagenomic-immunologic data", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "source": "Virginia Commonwealth University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Immuron Ltd.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Virginia Commonwealth University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}